Adicet Bio

Adicet Bio EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio (ACET) as of Oct 23, 2026 is -63.48 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -57.95 % — a change of 9.55% (lower).

EBIT/Assets

-63.48 %

YoY

9.55%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio is 2025 -63.48 % . Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio was 2024 -57.95 % . It decreases by 9.55% lower compared to the previous year.

The Adicet Bio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-13.61 USD
Jan 1, 2019
-38.47 USD
Jan 1, 2020
-25.48 USD
Jan 1, 2021
-18.30 USD
Jan 1, 2022
-21.94 USD
Jan 1, 2023
-73.34 USD
Jan 1, 2024
-57.95 USD
Jan 1, 2025
-63.48 USD
The Adicet Bio EBIT/Assets history
YEAREBIT/AssetsYoY
-63.48 %+9.55%
-57.95 %-20.99%
-73.34 %+234.30%
-21.94 %+19.86%
-18.30 %-28.15%
-25.48 %-33.78%
-38.47 %+182.65%
-13.61 %-60.21%
-34.21 %+18.50 M%
-0.00-100.00%
9.04 %+22.91%
7.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adicet Bio Stock analysis

What does Adicet Bio do? Adicet Bio, Inc. develops off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases, focusing on engineered gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies. The company's pipeline includes ADI-001 targeting CD20, ADI-002 targeting glypican 3 protein (GPC3), and ADI-00x for solid tumors and hematological indications. These therapies aim to enable selective tumor targeting, facilitate immune responses, and improve patient persistence. The company generates revenue through the development and potential commercialization of its pipeline products, with ADI-001, ADI-002, and ADI-00x representing key therapeutic candidates for oncology markets. Adicet Bio, Inc. is a biotechnology firm targeting the oncology sector with its gamma delta T cell therapies, designed to address unmet medical needs in cancer treatment. The company's product portfolio consists of ADI-001, ADI-002, and ADI-00x, each targeting specific antigens for tumor targeting. ADI-001 focuses on CD20, ADI-002 on GPC3, and ADI-00x on solid tumors and hematological conditions. These therapies are developed for potential commercialization in the biopharmaceutical market, where pharmaceutical companies and healthcare providers may purchase or license the therapies for patient treatment. The company's revenue model relies on the progression of its pipeline products through clinical development and eventual market entry. ADI-001, ADI-002, and ADI-00x are the primary products driving potential revenue, with ADI-001 and ADI-002 currently in development for specific cancer indications. The firm's focus on allogeneic therapies positions it to serve patients requiring off-the-shelf treatments, differentiating from autologous approaches. Adicet Bio, Inc. aims to secure partnerships or direct sales for its therapies, targeting oncology specialists and hospitals as key buyers in the healthcare ecosystem. Adicet Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adicet Bio stock

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio is -63.48 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio changed from -57.95 % to -63.48 %, representing a 9.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Adicet Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Adicet Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Adicet Bio

All Key Metrics — Adicet Bio